CENTURY II Bifurcation sub-analysis
5-year clinical outcomes of PCI-treated bifurcation lesions whereby a single stent approach was utilized in 93% of the cases showed similar good safety and efficacy for both Ulimaster™ and Xience stents.
Favorable TLF trend in true bifurcation subgroup, observed in Ultimaster™-DES-treated patients, warrant further exploration in larger cohorts.
Patient background and procedure
|mean + SD/ %||Ultimaster
|High-risk ACS (STEMI/NSTEMI)||15.8||18.2||0.66|
|Stent in MB and balloon in SB||45.0||48.6||0.68|
|Stent only in MB||48.0||43.8||0.58|
|Kissing balloon post-stent||50.0||50.5||0.95|
|N of implanted stents/ls||1.2±0.4||1.3±0.6||0.07|
|Total implanted stent length/pt||36.0±17.5||34.1±23.4||0.04|
5-year clinical outcomes
K Orvin et al, Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial, Catheter Cardiovasc Interv. 2016 May;87(6):1092-100.
Bernard Chevalier et al, Treatment of bifurcation lesions with a thin-strut drug eluting stent with bioresorbable polymer long-term clinical outcome of the CENTURY II trial, presented at EuroPCR 2019.